Koubková L - Search Results

1

Electrochemical analysis of a novel ferrocene derivative as a potential antitumor drug.

Bartošík M, Koubková L, Karban J, Červenková Šťastná L, Hodík T, Lamač M, Pinkas J, Hrstka R. Bartošík M, et al. Among authors: koubkova l. Analyst. 2015 Sep 7;140(17):5864-7. doi: 10.1039/c5an00958h. Analyst. 2015. PMID: 26203467

2

Evaluation of cytotoxic activity of titanocene difluorides and determination of their mechanism of action in ovarian cancer cells.

Koubkova L, Vyzula R, Karban J, Pinkas J, Ondrouskova E, Vojtesek B, Hrstka R. Koubkova L, et al. Invest New Drugs. 2015 Oct;33(5):1123-32. doi: 10.1007/s10637-015-0274-y. Epub 2015 Jul 24. Invest New Drugs. 2015. PMID: 26205069

3

Second primary cancers - causes, incidence and the future.

Koubková L, Hrstka R, Dobes P, Vojtesek B, Vyzula R. Koubková L, et al. Klin Onkol. 2014;27(1):11-7. doi: 10.14735/amko201411. Klin Onkol. 2014. PMID: 24635432 Review.

4

[Next generation sequencing - application in clinical practice].

Koubková L, Vojtěšek B, Vyzula R. Koubková L, et al. Klin Onkol. 2014;27 Suppl 1:S61-8. doi: 10.14735/amko20141s61. Klin Onkol. 2014. PMID: 24945539 Review. Czech.

5

Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.

Hašková P, Koubková L, Vávrová A, Macková E, Hrušková K, Kovaříková P, Vávrová K, Simůnek T. Hašková P, et al. Among authors: koubkova l. Toxicology. 2011 Nov 18;289(2-3):122-31. doi: 10.1016/j.tox.2011.08.006. Epub 2011 Aug 12. Toxicology. 2011. PMID: 21864640

6

Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.

Hašková P, Kovaříková P, Koubková L, Vávrová A, Macková E, Simůnek T. Hašková P, et al. Among authors: koubkova l. Free Radic Biol Med. 2011 Feb 15;50(4):537-49. doi: 10.1016/j.freeradbiomed.2010.12.004. Epub 2010 Dec 13. Free Radic Biol Med. 2011. PMID: 21147217

7

[Immunotherapy of Bronchogenic Carcinoma and Its Perspectives].

Koubková L. Koubková L. Klin Onkol. 2015;28 Suppl 4:4S77-81. doi: 10.14735/amko20154s77. Klin Onkol. 2015. PMID: 26647894 Review. Czech.

8

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.

9

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.

Bratova M, Skrickova J, Matusikova M, Hrabcova K, Havel L, Koubkova L, Hrnciarik M, Krejci J, Fischer O, Svaton M, Brat K. Bratova M, et al. Among authors: koubkova l. J Cancer Res Clin Oncol. 2023 Dec;149(19):17123-17131. doi: 10.1007/s00432-023-05431-5. Epub 2023 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 37768380 Free PMC article.

10

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer.

Blazek J, Hosek P, Hrabcova K, Bratova M, Kultan J, Hrnciarik M, Cernovska M, Zemanova P, Krejci J, Koubkova L, Stastny M, Svaton M. Blazek J, et al. Among authors: koubkova l. In Vivo. 2023 Sep-Oct;37(5):2229-2236. doi: 10.21873/invivo.13324. In Vivo. 2023. PMID: 37652490 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page